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ABSTRACT  
Evidences support the fact that sickle cell disease (SCD) is associated with a chronic inflammatory state characterized by haemolysis. C-reactive 
protein level (CRP) and white blood cell (WBC) count considered as biomarkers for inflammation. Also, elevation of serum total lactate 
dehydrogenase (LDH) levels are found to be associated with haemolysis, this makes LDH a nonspecific marker which has to be interpreted in a 
context of other markers of disease. The present study aims to assess the role of CRP levels, WBC counts, RBC counts, haemoglobin (Hb) 
concentrations and LDH levels in sickle hemoglobin (HbS) patients. Blood samples of 10 HbS patients (six females and four males) attending 
M.Y. Hospital, Indore during the period of Aug to Oct 2019 were screened for CRP, LDH and Hb levels and RBC and WBC counts using latex 
enhanced immune-turbidimetric assay, LDH optimize DGKC kinetic and differential automated hematology analyzer respectively. Data (mean ± 
SEM) was analyzed using Graphpad Prism software using Tukey’s multiple comparison post-hoc test. The mean Hb levels (7.73 ± 0.81 g/dl) and 
RBC counts (3.21 ± 0.53 million/µl) were found to be significantly decreased (p˂ 0.001 and 0.01 respectively) and mean WBC co unts (15214.28 
± 1893.40 per mm3), CRP levels (85.73 ± 23.23 mg/l) and LDH levels (1334.00 ± 418.49 U/l) were found to be significantly increased (p˂ 
0.0001, 0.01 and 0.01 respectively) in HbS patients in comparison with their respective controls. The variations in serum LDH and CRP levels 
are accompanied by changes in hematological parameters in HbS patients. These parameters may be considered as indicator of the severity of 
the disease. 
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Sickle cell disease (SCD) or sickle cell anemia (SCA) is a 
recessive genetic disorder resulting in red blood cells 
forming into a sickled shape.1-3 The disease affected millions 
of people throughout the world and is particularly common 
among those whose ancestry comes from sub-Saharan Africa, 
Spanish-speaking regions in the Western Hemisphere (i.e., 
South America, the Caribbean and Central America), Saudi 
Arabia, India and Mediterranean countries such as Turkey, 
Greece and Italy.4 SCD is the most commonly found 
monogenic disease and has been recognized by the World 
Health Organization (WHO) as major public health problem.5 
causing morbidity and mortality with tremendous social and 
economic impact mainly due to the recurrent acute episodic 
clinical events called “crises” and hospitalization.6  
Common and important morbidities associated with SCD are 
vaso-occulsive episode7,8 including haemolysis, 
inflammation, infections,9 acute chest syndrome,10 stroke,11 
renal failure,12 hip necrosis and early deaths.13 Although 
there have been some advance in the management of SCD, 
much remains to be learned about the mechanism 
underlying the wide phenotypic diversity of the disease. In 
resources poor countries, basic facilities for diagnosis and 
management are lacking, systematic screening is not 
common practice and diagnosis is made late. The analysis of 
β-globin gene haplotypes in India using PCR-RFLP revealed 
four haplotypes, Arab-Indian, Senegal, Benin and Bantu/CAB, 
whereas the Cameroon haplotype did not found in the study 
subjects. The Arab-Indian haplotype was found most 
common haplotype (78%) along with atypical haplotypes 
(15%). Senegal, Benin and Bantu haplotypes were found in 
4%, 2% and 1% respectively of these sickle cell disease 
patients.14 
Some biomarkers have important role in the identification, 
understanding pathophysiological processes and 
management of SCD.15 Vaso-occlusive crisis activate and 
damages the endothelial cells with activation of adhesion 
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molecules that lead to inflammation, release of C‑reactive 
protein (CRP) and other inflammatory mediators and 
subsequent enhancement of ischemia.16 Production of CRP is 
a part of a nonspecific acute phase response to inflammation 
and tissue necrosis.17 Elevated levels of CRP, as a general 
biomarker of inflammation have been previously reported in 
sickle hemoglobin (HbS) patients.18,19 White blood cell 
(WBC) count is also be considered as a biomarker of 
inflammation.20 As the frequency of vaso-occlusive episodes 
was a marker of poorer survival in patients with sickle cell 
anemia,21 the study of this biomarkers may help in 
prevention of vaso-occlusive crisis. 
Lactate dehydrogenase (LDH) is present in all the body cells 
and is found in high concentration in muscle cells, kidneys, 
erythrocytes, leucocytes, lungs, lymph nodes, spleen and 
brain. The elevation of LDH was associated with hemolysis, 
pain crisis, pulmonary hypertension, kidney damage and 
endothelial activation with elevated soluble vascular 
adhesion molecules.22 This makes LDH a nonspecific marker 
which has to be interpreted in a context of other markers of 
disease. Serum LDH level is elevated above the reference 
range in hemolytic states and this has been demonstrated in 
studies done on SCD patients. These studies have 
demonstrated a correlation between the serum LDH level 
and other markers of hemolysis such as bilirubin.23 Also, red 
blood cell (RBC) count and haemoglobin (Hb) concentration 
alters in hemolysis. The identification of LDH may be 
considered as marker of hemolysis and might be an 
important tool for the early detection of the severity of the 
disease in HbS patients. 
The prevalence of sickle cell carriers among different tribal 
groups of India varies from 1-40%. In Jabalpur, Madhya 
Pradesh, newborn screening has just been initiated. In India, 
Madhya Pradesh state has the highest load with sickle cell 
disease and the prevalence of HbS varies from 10-33%.24 
Therefore, it was found worth to screen the Indore region of 
Madhya Pradesh for our study. The present study aims to 
assess the role of CRP levels, WBC counts, RBC counts, 
haemoglobin (Hb) concentrations and LDH levels in sickle 
hemoglobin (HbS) patients. 
MATERIAL AND METHODS 
Study Area and Design 
This pilot study was conducted in Maharaja Yashwant Rao 
Hospital, Indore, Madhya Pradesh, India. This is a case 
control study included a total of ten patients (six females and 
four males) all of them were diagnosed with sickle cell 
anemia with Hb Electrophoresis and hospitalized. Six healthy 
females and four healthy males were included in the control 
group. Patients use hydroxyurea or any treatment which 
affect the results and in cooperation patients were excluded 
from the study. This study was approved by the Ethical 
Committee of Mahatma Gandhi Memorial Medical College, 
Indore and written informed consent was obtained from 
each participant before sample collection.  
Sample Collection and Laboratory Analysis  
In this pilot study, blood samples of ten HbS patients 
attending M.Y. Hospital, Indore during the period of Aug to 
Oct 2019 were screened for CRP, LDH and Hb levels and RBC 
and WBC counts. A sample of 5 ml of blood was collected 
from each participant, from which 3 ml was dispensed into 
ethylene diamine tetra acetic acid (EDTA) containing tubes 
for determination of Hb concentration, WBC and RBC count 
and 2 ml into plain tubes for determination of CRP and LDH 
concentration. The serum level of CRP was assayed using 
latex enhanced immune-turbidimetric assay using an 
automated clinical chemistry analyzer (Randox Laboratories 
Ltd., UK). LDH was measured using LDH optimize DGKC 
kinetic method kits (ERBA Diagnostic, Mannheim, Germany). 
Hb levels and RBC and WBC counts were determined using 
differential automated hematology analyzer (LH-750, 
Beckman Coulter, USA). 
Statistical Analysis 
Results were expressed as mean ± S.E.M. The data were 
analyzed by one-way analysis of variance (ANOVA) tracked 
by Tukey's multiple comparison tests. Probability values less 
than 0.05 were considered statistically significant in all the 
cases 
RESULT 
The mean Hb levels (7.73 ± 0.81 g/dl) and RBC counts (3.21 
± 0.53 million/µl) were found to be significantly decreased 
(p˂ 0.001 and 0.01 respectively) and mean WBC counts 
(15214.28 ± 1893.40 per mm3), CRP levels (85.73 ± 23.23 
mg/l) and LDH levels (1334.00 ± 418.49 U/l) were found to 
be significantly increased (p˂ 0.0001, 0.01 and 0.01 
respectively) in HbS patients in comparison with their 
respective controls (table 1 and figure 1). 
 
 
Table 1: Comparison of some hematological parameters and serum LDH and CRP levels of sickle cell anemic patients 
with normal individuals 
S.No. Parameter Value (Mean ± S.E.M.) 
Patient Group Control Group 
1 Hemoglobin concentration (g/dl) 7.73 ± 0.81 15.98± 1.06* 
2 RBC count (million/µl) 3.21 ± 0.53 5.07 ± 0.69# 
3 WBC count (per mm3) 15214.28 ± 1893.40 6586.88 ± 545.17& 
4 CRP level (mg/l) 85.73 ± 23.23 6.26 ± 0.73# 
5 LDH level (U/l) 1334.00 ± 418.49 428.95 ±51.64# 
Results are expressed as Mean ± S.E.M.; n = 10 in each group. Data was analyzed by one-way ANOVA followed by Tukey’s multiple comparison 
test. Significance: *p< 0.001, #p< 0.01 and &p< 0.0001 when compared with respective control group. RBC: red blood cells; WBC: white blood 
cells; CRP: C-reactive protein; LDH: lactate dehydrogenase. 
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Figure 1: Comparison of some hematological parameters and serum LDH and CRP levels of sickle cell anemic patients 
with normal individuals 
Results are expressed as Mean ± S.E.M.; n = 10 in each group. Data was analyzed by one way ANOVA followed by Tukey’s multiple comparison 
test. Significance: *p< 0.001, #p< 0.01and &p< 0.0001when compared with respective control group. Hb: hemoglobin; RBC: red blood cells; WBC: 
white blood cells; CRP: C-reactive protein; LDH: lactate dehydrogenase. 
 
DISCUSSION 
In this study the mean Hb levels and RBC counts were found 
to be significantly decreased and mean WBC counts and LDH 
levels were found to be significantly increased in HbS 
patients in comparison with their respective controls. 
LDH is considered a marker of haemolysis and an indicator 
of risk of morbidity and mortality in HbS patients.25 Our 
study showed that the values of Hb concentration and RBC 
count of HbS patients are lower than those of control 
subjects. The low rate of Hb in sickle cell patients is due to 
chronic haemolysis.22  In this pilot study, the number of WBC 
of HbS patients was higher compared to non-SCD subjects 
and our finding agreed with previous study conducted by 
Krishnan et al. (2010).26 It has been shown that the leukocyte 
is an important factor that leads to the hyper viscosity and 
the phenomenon of endothelial adhesion.27 
In this study, we found that CRP level was higher in HbS 
patients than in control group individuals and this result is in 
agreement with a study conducted by Okocha et al. (2014).28 
Additionally, most of the HbS patients developed one of the 
complications specially the vaso-occlusive crisis which is the 
most frequent and if not diagnosed early they may develop 
organ damage and die in early age. So, the early prediction of 
vaso-occlusive crisis by the detection of the CRP level which 
might be beneficial in disease management. 
CONCLUSION 
The conducted study confirmed that variation in serum LDH 
and CRP levels are accompanied by changes in hematological 
parameters in HbS patients. These parameters may be 
considered as indicator of the severity of the disease and 
may have a clinical impact in the prevention and 
management of vaso-occlusive crisis in Indian HbS patients. 
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